HIG
78
6
HAL
50
6
ILMN
28
-2
EOG
39
3
ALLE
35
-11
L
62
3
GWW
41
2
GPC
53
2
MU
60
9
IVZ
39
7
AKAM
35
3
HOG
44
2
JCI
45
4
PNC
55
3
ES
43
4
M
27
-3
AME
54
6
NSC
42
3
CMCSA
48
2
ACN
29
-4
HIG
78
6
HAL
50
6
ILMN
28
-2
EOG
39
3
ALLE
35
-11
L
62
3
GWW
41
2
GPC
53
2
MU
60
9
IVZ
39
7
AKAM
35
3
HOG
44
2
JCI
45
4
PNC
55
3
ES
43
4
M
27
-3
AME
54
6
NSC
42
3
CMCSA
48
2
ACN
29
-4
Financhill
Back

Intra-Cellular Therapies 10K Form

Buy
59

ITCI
Intra-Cellular Therapies

Last Price:
$131.27
Seasonality Move:
6.95%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ITCI News And Ratings

See the #1 stock for the next 7 days that we like better than ITCI

ITCI Financial Statistics

Sales & Book Value

Annual Sales: $680.5M
Cash Flow: $-12.7M
Price / Cash Flow: 0
Annual Sales: $10.81
Price / Book: 12.15

Profitability

EPS (TTM): -0.73000
Net Income (TTM): $-74.7M
Gross Margin: $623.5M
Return on Equity: -8.07%
Return on Assets: -6.81%

Intra-Cellular Therapies Earnings Forecast

Key Intra-Cellular Therapies Financial Ratios

  • The Gross Profit Margin over the past 11 years for ITCI is 91.63%.
  • The Selling, General & Administrative Expenses for ITCI have been equal to 74.13% of Gross Profit Margin.
  • The Research & Development expenses have been 34.70% of Revenue.
  • Per Share Earnings over the last 13 years have been positive in 7 years.

Intra-Cellular Therapies Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: ITCI
CUSIP: 46116X
Website: intracellulartherapies.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.36
Quick Ratio: 5.68

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 35.45

ITCI Technical Analysis vs Fundamental Analysis

Buy
59
Intra-Cellular Therapies (ITCI) is a Buy

Is Intra-Cellular Therapies a Buy or a Sell?